Education
About Us
Working with TipRanks
Follow Us
XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB)
NASDAQ:XTLB
RESEARCH TOOLSreports
Top Page
XTL Biopharmaceuticals Sponsored ADR
(NASDAQ:XTLB)
Rating:39Underperform
Price Target:―
XTL Biopharmaceuticals Sponsored ADR (XTLB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.29M
Dividend YieldN/A
Average Volume (3M)11.53K
Price to Earnings (P/E)―
Beta (1Y)0.97
Revenue GrowthN/A
EPS Growth86.44%
CountryUS
Employees10
SectorHealthcare
Sector Strength43
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.14
Shares Outstanding8,813,852
10 Day Avg. Volume7,456
30 Day Avg. Volume11,534
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
XTL Biopharmaceuticals Sponsored ADR Business Overview & Revenue Model
Company DescriptionXTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) is a biopharmaceutical company focused on the development, acquisition, and commercialization of pharmaceutical products for the treatment of unmet medical needs, primarily in the fields of autoimmune diseases and oncology. The company operates within the biotechnology and pharmaceutical sectors and is dedicated to advancing its pipeline of therapeutic candidates through clinical trials and strategic collaborations.
How the Company Makes MoneyXTL Biopharmaceuticals generates revenue primarily through the development and commercialization of proprietary drug candidates targeting autoimmune diseases and cancer. The company may earn money from licensing agreements, milestone payments, and royalties related to its drug development programs. Key revenue streams include partnerships with other pharmaceutical companies for the co-development or out-licensing of its drug candidates, as well as potential sales of approved products. Additionally, the company may receive research grants and funding from governmental or non-governmental organizations to support its R&D activities.
XTL Biopharmaceuticals Sponsored ADR Financial Statement Overview
Summary
XTL Biopharmaceuticals Ltd. faces ongoing financial headwinds, with significant net losses and negative EBIT margins. Despite a slight improvement in stockholders' equity, the company struggles with high liabilities and negative cash flows, reflecting operational inefficiencies typical in the biotech sector.Income Statement
The income statement reflects significant challenges with persistent net losses and negative EBIT margins due to the absence of revenue. The company's profitability trajectory is concerning, with inconsistent net income figures over the years. The lack of revenue growth further exacerbates the financial instability, indicating potential operational inefficiencies in the biotechnology sector.20
Very Negative
Balance Sheet
The balance sheet shows a slight improvement in stockholders' equity, moving from negative to positive in the most recent year. However, the overall financial stability remains weak due to high liabilities relative to assets. The company benefits from a low debt profile, but the equity ratio indicates a fragile financial structure that may pose risks in sustaining operations.40
Negative
Cash Flow
The cash flow statement reveals consistent negative free cash flow and operating cash flow, highlighting liquidity challenges. The cash flow to net income ratios indicate inefficiencies in converting net losses to positive cash flow. Although there is some improvement in cash flow from investing activities, the overall cash flow management remains a concern.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 162.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 162.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| -1.36M | -765.00K | -880.00K | -1.03M | -948.00K | -842.00K | EBITDA |
| -865.75K | -764.00K | -879.00K | -1.03M | -947.00K | 0.00 | Net Income Common Stockholders |
| -772.28K | -1.78K | -1.35M | 435.00K | -782.00K | -1.35M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 251.00K | 2.01M | 3.72M | 6.13M | 6.04M | 6.73M | Total Assets |
| 511.00K | 2.43M | 4.19M | 6.62M | 6.50M | 7.21M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -251.00K | -1.40M | -2.09M | -2.97M | -3.63M | -4.46M | Total Liabilities |
| 733.00K | 206.00K | 187.00K | 1.28M | 254.00K | 232.00K | Stockholders Equity |
| -222.00K | 2.22M | 4.00M | 5.33M | 6.25M | 6.98M |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | -707.00K | -901.00K | -1.05M | -851.00K | -910.00K | Operating Cash Flow |
| 0.00 | -707.00K | -901.00K | -1.05M | -850.00K | -908.00K | Investing Cash Flow |
| 0.00 | 41.00K | 36.00K | 8.00K | 32.00K | 2.11M | Financing Cash Flow |
| 0.00 | 0.00 | 0.00 | 385.00K | 0.00 | 0.00 |
XTL Biopharmaceuticals Sponsored ADR Technical Analysis
Negative
1.08
Price Trends
1.22
Negative
1.43
Negative
1.80
Negative
Market Momentum
-0.05
Positive
40.22
Neutral
11.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTLB, the sentiment is Negative. The current price of 1.08 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.22, and below the 200-day MA of 1.80, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 40.22 is Neutral, neither overbought nor oversold. The STOCH value of 11.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XTLB.
XTL Biopharmaceuticals Sponsored ADR Risk Analysis
XTL Biopharmaceuticals Sponsored ADR disclosed 38 risk factors in its most recent earnings report. XTL Biopharmaceuticals Sponsored ADR reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XTL Biopharmaceuticals Sponsored ADR Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $5.63B | 140.16 | 19.70% | ― | 33.54% | -6.13% | |
54 Neutral | $1.00B | ― | -57.92% | ― | -13.37% | 2.57% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
46 Neutral | $619.93M | ― | -343.83% | ― | 387.20% | 21.00% | |
43 Neutral | $92.63M | ― | -44.89% | ― | ― | 64.71% | |
43 Neutral | $30.04M | ― | -43.47% | ― | -98.13% | -129.06% | |
39 Underperform | $10.29M | ― | -26.83% | ― | ― | 86.44% |
* Healthcare Sector Average
Performance Comparison
XTLB
XTL Biopharmaceuticals Sponsored ADR
1.08
-1.53
-58.62%
TGTX
TG Therapeutics
34.24
17.53
104.91%
SCYX
SCYNEXIS
0.77
-1.58
-67.23%
CRBP
Corbus Pharmaceuticals
7.54
-37.48
-83.25%
NTLA
Intellia Therapeutics
9.46
-15.38
-61.92%
ANAB
AnaptysBio
20.74
-3.17
-13.26%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.